Ching-Yan Zhu, Jing-Nan Zhang, Yi-Kei Tse, Qing-Wen Ren, Jia-Yi Huang, Si-Yeung Yu, Ran Guo, Wen-Li Gu, Daniel Tai-Leung Chan, Gregory Y H Lip, Kai-Hang Yiu
{"title":"Prevalence, Clinical Characteristics and Prognosis of Vascular Disease in Valvular Heart Surgery: A Multi-Centre Study.","authors":"Ching-Yan Zhu, Jing-Nan Zhang, Yi-Kei Tse, Qing-Wen Ren, Jia-Yi Huang, Si-Yeung Yu, Ran Guo, Wen-Li Gu, Daniel Tai-Leung Chan, Gregory Y H Lip, Kai-Hang Yiu","doi":"10.5334/gh.1462","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The clinical significance of atherosclerotic disease in more than one vascular bed, that is, polyvascular disease, in valvular heart surgery remains poorly understood. This study aims to establish the prevalence and prognostic value of polyvascular disease for long-term outcomes after valvular heart surgery.</p><p><strong>Methods: </strong>Patients receiving valvular heart surgery at two tertiary centres from January 1, 2010 to December 31, 2021 were identified. We examined the effect of atherosclerotic disease in three major vascular beds, including coronary artery disease (CAD), ischaemic cerebrovascular accidents (CVA) and peripheral vascular disease (PVD), on postoperative major adverse cardiac events (MACE) and all-cause mortality. Polyvascular disease was defined as atherosclerotic disease in ≥2 vascular beds.</p><p><strong>Results: </strong>Of 3843 patients (mean age 58 ± 13 years; 52% male), 1266 (33%) had atherosclerotic disease in ≥1 vascular beds, including 207 (5.4%) with polyvascular disease. Patients with vascular disease were older with more comorbidities, higher surgical risk and more aortic stenosis. Over a median follow-up of 6.37 years (IQR: 3.40-9.54), patients with polyvascular disease had the greatest long-term MACE risk [HR: 1.68 (1.35-2.10)], followed by those with monovascular disease [HR: 1.43 (1.24-1.65)]. Both monovascular and polyvascular disease independently predicted mortality and MACE. Patients with extracardiac vascular disease had independently greater long-term MACE risk than CAD [HR: 1.56 (1.27-1.92)].</p><p><strong>Conclusion: </strong>Patients undergoing valvular heart surgery exhibit a high prevalence of vascular disease. The risk of adverse outcomes rises with both the presence and extent of vascular disease, and extracardiac vascular disease confers greater risk of MACE than CAD.</p>","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"71"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396194/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1462","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The clinical significance of atherosclerotic disease in more than one vascular bed, that is, polyvascular disease, in valvular heart surgery remains poorly understood. This study aims to establish the prevalence and prognostic value of polyvascular disease for long-term outcomes after valvular heart surgery.
Methods: Patients receiving valvular heart surgery at two tertiary centres from January 1, 2010 to December 31, 2021 were identified. We examined the effect of atherosclerotic disease in three major vascular beds, including coronary artery disease (CAD), ischaemic cerebrovascular accidents (CVA) and peripheral vascular disease (PVD), on postoperative major adverse cardiac events (MACE) and all-cause mortality. Polyvascular disease was defined as atherosclerotic disease in ≥2 vascular beds.
Results: Of 3843 patients (mean age 58 ± 13 years; 52% male), 1266 (33%) had atherosclerotic disease in ≥1 vascular beds, including 207 (5.4%) with polyvascular disease. Patients with vascular disease were older with more comorbidities, higher surgical risk and more aortic stenosis. Over a median follow-up of 6.37 years (IQR: 3.40-9.54), patients with polyvascular disease had the greatest long-term MACE risk [HR: 1.68 (1.35-2.10)], followed by those with monovascular disease [HR: 1.43 (1.24-1.65)]. Both monovascular and polyvascular disease independently predicted mortality and MACE. Patients with extracardiac vascular disease had independently greater long-term MACE risk than CAD [HR: 1.56 (1.27-1.92)].
Conclusion: Patients undergoing valvular heart surgery exhibit a high prevalence of vascular disease. The risk of adverse outcomes rises with both the presence and extent of vascular disease, and extracardiac vascular disease confers greater risk of MACE than CAD.
Global HeartMedicine-Cardiology and Cardiovascular Medicine
CiteScore
5.70
自引率
5.40%
发文量
77
审稿时长
5 weeks
期刊介绍:
Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources.
Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention.
Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.